Press Release: DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC were progression free at 4.5 years1 AURIGA study shows higher rates of MRD negative conversion in subgroup patient populations disproportionately impacted by multiple myeloma2
Press Release: DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis - Newscast
Mon, 10 Mar 2025 11:13:00 GMT Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. | Johnson & Johnson is ...
Fri, 21 Feb 2025 16:00:00 GMT Darzalex, a first-in-class treatment ... the estimated median overall survival for single-agent daratumumab in these heavily pre-treated patients was 20 months. The overall response rate (ORR ...
Wed, 05 Feb 2025 23:52:00 GMT HLX15 is being developed as a biosimilar of Darzalex® & Darzalex Faspro ... Disclaimer: This press release may include statements of future expectations and other forward-looking statements ...
Wed, 22 Jan 2025 10:22:00 GMT has reported its net sales for DARZALEX® (daratumumab) for the year 2024. The announcement was made in a Form 6-K report filed with the SEC today. According to InvestingPro analysis, the company ...
Tue, 21 Jan 2025 22:23:00 GMT COPENHAGEN, Denmark; January 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ...
